Articles

WellPoint insures two-thirds of Hoosier workers

Indianapolis-based WellPoint claimed 63 percent of all employees covered by small-group employers and 66 percent of the workers at large-group employers, according to Seattle-based actuarial firm Milliman Inc.

Read More

Primary care gets a new approach: prevention

A budding model for primary care that encourages the family doctor to act as a health coach who focuses as much on preventing illness as on treating it has shown promising results and saved insurers millions of dollars.

Read More

FDA says potential diabetes drug may cause cancer

Dapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar drugs.

Read More

CBO: No great savings from health reform

Don’t expect the health reform law to tame health care costs. That’s the conclusion of the director of the Congressional Budget Office, who also suggested some of the simplest ways to moderate costs would be to roll back some of its key provisions.

Read More

Exchange could snag 1.1M Hoosiers

An estimated 1.1 million Hoosiers will obtain health insurance through a yet-to-be-created online exchange, according to the latest estimates from the task force guiding Indiana’s response to the 2010 health reform law.

Read More

Study: Medicaid better than nothing

Health care reform will add roughly 500,000 Hoosiers to the Medicaid program and, in spite of great criticism of that expansion, a new study suggests Medicaid coverage does help consumers get more care, have fewer unpaid bills and feel better.

Read More

Employers face messy decision to drop health insurance

Companies that drop insurance coverage could, without spending any more money than they are now, give workers an 11-percent raise or else help them save as much as $2,000 per year buying health coverage in one of the exchanges, IBJ calculations show.

Read More

Lilly loses bid to end revived Zyprexa U.K. patent case

The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.

Read More